The Journal of Allergy and Clinical Immunology
Volume 125, Issue 2 , Pages 411-418.e4, February 2010

Stimulation of human T cells with sulfonamides and sulfonamide metabolites

  • J. Luis Castrejon, BSc

      Affiliations

    • MRC Centre for Drug Safety Science, Department of Pharmacology, University of Liverpool, Liverpool, United Kingdom
  • ,
  • Neil Berry, PhD

      Affiliations

    • Department of Chemistry, University of Liverpool, Liverpool, United Kingdom
  • ,
  • Sabah El-Ghaiesh, BSc

      Affiliations

    • MRC Centre for Drug Safety Science, Department of Pharmacology, University of Liverpool, Liverpool, United Kingdom
  • ,
  • Basil Gerber, PhD

      Affiliations

    • Division of Allergology, Clinic of Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern, Switzerland
  • ,
  • Werner J. Pichler, MD

      Affiliations

    • Division of Allergology, Clinic of Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern, Switzerland
  • ,
  • B. Kevin Park, PhD

      Affiliations

    • MRC Centre for Drug Safety Science, Department of Pharmacology, University of Liverpool, Liverpool, United Kingdom
  • ,
  • Dean J. Naisbitt, PhD

      Affiliations

    • MRC Centre for Drug Safety Science, Department of Pharmacology, University of Liverpool, Liverpool, United Kingdom
    • Corresponding Author InformationReprint requests: Dean J. Naisbitt, PhD, MRC Centre for Drug Safety Science, Department of Pharmacology, Sherrington Building, Ashton Street, the University of Liverpool, Liverpool, L69 3GE, United Kingdom.

Received 6 August 2009; received in revised form 16 October 2009; accepted 19 October 2009.

Background

Exposure to sulfonamides is associated with a high incidence of hypersensitivity reactions. Antigen-specific T cells are involved in the pathogenesis; however, the nature of the antigen interacting with specific T-cell receptors is not fully defined.

Objective

We sought to explore the frequency of sulfamethoxazole (SMX)– and SMX metabolite–specific T cells in hypersensitive patients, delineate the specificity of clones, define mechanisms of presentation, and explore additional reactivity with structurally related sulfonamide metabolites.

Methods

SMX- and SMX metabolite–specific T-cell clones were generated from 3 patients. Antigen specificity, mechanisms of antigen presentation, and cross-reactivity of specific clones were then explored. Low-lying energy conformations of drugs (metabolites) were modeled, and the energies available for protein binding was estimated.

Results

Lymphocytes proliferated with parent drugs (SMX, sulfadiazine, and sulfapyridine) and both hydroxylamine and nitroso metabolites. Three patterns of drug (metabolite) stimulation were seen: 44% were SMX metabolite specific, 43% were stimulated with SMX metabolites and SMX, and 14% were stimulated with SMX alone. Most metabolite-responsive T cells were stimulated with nitroso SMX–modified protein through a hapten mechanism involving processing. In contrast to SMX-responsive clones, which were highly specific, greater than 50% of nitroso SMX–specific clones were stimulated with nitroso metabolites of sulfapyridine and sulfadiazine but not nitrosobenzene. Pharmacophore modeling showed that the summation of available binding energies for protein interactions and the preferred spatial arrangement of atoms in each molecule determine a drug's potential to stimulate specific T cells.

Conclusions

Nitroso sulfonamide metabolites form potent antigenic determinants for T cells from hypersensitive patients. T-cell responses against drugs (metabolites) bound directly to MHC or MHC/peptide complexes can occur through cross-reactivity with the haptenic immunogen.

Key words: Human, T cells, drug hypersensitivity, drug metabolism

Abbreviations used: SD, Sulfadiazine, SMX, Sulfamethoxazole, SMX-NHOH, Sulfamethoxazole hydroxylamine, SMX-NO, Nitroso sulfamethoxazole, SP, Sulfapyridine

 

 Declaration of funding sources: J.L.C. is a PhD student funded by the Mexican National Council for Science and Technology (CONACyT). This work was funded by a grant from the Wellcome Trust (078598/Z/05/Z) as part of the Centre for Drug Safety Science supported by the Medical Research Council (G0700654).

 Disclosure of potential conflict of interest: W. J. Pichler has received research support from the Swiss National Foundation. B. K. Park has received research support from the Medical Research Council (UK), Wellcome Trust, and AstraZeneca. D. J. Naisbitt has received research support from the Medical Research Council (UK) and Wellcome Trust. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)01567-X

doi:10.1016/j.jaci.2009.10.031

The Journal of Allergy and Clinical Immunology
Volume 125, Issue 2 , Pages 411-418.e4, February 2010